The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.35
Bid: 13.20
Ask: 13.50
Change: 0.00 (0.00%)
Spread: 0.30 (2.273%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 13.35
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

Thu, 31st Mar 2022 21:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

SSE PLC - FTSE 100-listed Perth, Scotland-based energy company - SSEN Transmission subsidiary agrees GBP350 million private placement. Placement will be issued in two tranches: a GBP175 million, 10-year note at a rate of 3.13% and a GBP175 million, 15-year note at a rate of 3.24%. "The proceeds are earmarked to fund part of SSEN Transmission's programme of critical investments in transmission network infrastructure that will help accommodate the significant increase in renewables required to bolster the UK's energy security and achieve the transition to net zero emissions, as well as cover existing maturing debt," company explains.

----------

Croda International PLC - FTSE 100-listed Yorkshire, England-based chemicals maker - Wins GBP15.9 million UK government grant to expand its manufacturing facility in Leek, Staffordshire. "The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines," company explains. Adds that it will also chip in GBP15.9 million to help the expansion. Daniele Piergentili, president of Croda Life Sciences says: "This investment will meaningfully enhance our lipid system capability and manufacturing capacity, ensuring that Croda plays a central role in both the development and future supply of this important delivery technology."

----------

Mobeus Income & Growth VCT PLC - venture capital trust managed by Gresham House Asset Management Ltd - Net asset value per share ends 2021 at 90.31 pence, rising from 67.03p at the same point the year prior. Annual dividend slips to 9.00p from 11.00p. Total NAV return in 2021 was 42.2%. Chair Clive Boothman says: "Although this period has been marked by continued challenges, the portfolio has proven to be resilient and adaptive in facing them. The way in which businesses have been able to identify and capitalise on new opportunities in the changing UK consumer and business environment has been satisfying."

----------

Henderson High Income Trust PLC - pure income trust investing in dividend-paying UK companies - Net asset value per share ends 2021 at 177.92 pence, rising from 157.25p at the same point the year prior. Annual dividend increases slightly to 9.95p from 9.90p. Total NAV return 19.8% in 2021, which outperforms benchmark which saw a return of 14.1%. Chair Jeremy Rigg says: "A number of factors contributed to the outperformance versus the benchmark return. In particular, the company's asset allocation was helpful due to an overweight position in equities and an underweight position in bonds relative to the benchmark. The company's gearing was also beneficial during a period of positive returns for the UK equity market as was the bond portfolio, which outperformed its benchmark by an impressive 5.8% in 2021 due to good stock selection."

----------

Invesco Bond Income Plus Ltd - investment company focused on bonds and other fixed-interest securities - Net asset value per share ends 2021 at 193.82 pence, slipping from 194.29p at same point year prior. Annual dividend grows to 10.75p from 10.00p. Total NAV return in 2021 5.3%, slowing from 6.9% return in 2020, but outperforms ICE BofA European Currency High Yield Index return of 4.0%. Chair Tim Scholefield says: "In the shorter term we could well see nerves tested and increasing market volatility. However, we are inclined to view this prospect as a temporary period of turbulence likely to provide attractive opportunities for our type of fundamental, longer term investment approach."

----------

BMO Real Estate Investments Ltd - real estate investment trust - Net asset value per share ends 2021 at 121.0 pence, rising from 102.1p six months earlier. EPRA earnings per share in first half grows to 2.0p from in same period year prior 1.8p. "The UK real estate market enjoyed its highest total returns for seven years in 2021. Against this background, the group has generated a very positive outcome over the last 6 months," Chair Vikram Lall says. Company adds: "The group's property portfolio delivered a total return of 16.3% over the six-month period, showing significant outperformance against the MSCI return of 10.5%. The outperformance was largely driven by capital growth, although the portfolio also continued to maintain a yield advantage through an enhanced income return."

----------

Renewables Infrastructure Group Ltd - Guernsey-based renewable energy investor advised by InfraRed Capital Partners - Buys 49% equity interest in Project Valdesolar, an operating solar park in the province of Badajoz, Spain, from Repsol, a Spanish-listed global energy company. Repsol developed and built Valdesolar, and will retain a 51% equity interest in the project. No financial details disclosed.

----------

BiON PLC - Kuala Lumpur-based renewable energy services - Enters agreement to sell BiON Ventures Sdn Bhd, its main operational subsidiary, to Minnos Ventures Inc. After deal, company will become cash shell. The consideration for the proposed disposal is GBP1.00, as it does not have sufficient resources to run business. "As regards the Group's operations, the four existing biogas power plants have for various reasons been producing only 1MW out of the 7MW capacity to the National Grid and a new 3MW plant in Indonesia remains under construction. To upgrade and repair the existing plants would require some MYR12 million, about USD2.9 million, and completion of the Indonesian plant another MYR10 million. The company does not have access to such funding," company explains. Company also conditionally raises GBP1 million from placing at 0.3 pence per share, which will be used be used to settle outstanding creditors of the company, with the remainder - GBP600,000 - to be used to search for acquisition opportunities.

----------

Love Hemp Group PLC - London-based cannabidiol products - Pretax loss in six months to December 31 widens to GBP5.1 million from GBP1.2 million in same period a year prior. Revenue slips to GBP1.7 million from GBP2.4 million. Administrative expenses rises to GBP5.5 million from GBP2.8 million. Chair Andrew Male says first half performance was "disappointing". The widened loss, he continues: "reflects the planned and significant investment Love Hemp has made in marketing and brand building. Included in this are the administration costs associated with the licensing agreement with the UFC and the agreement with former world heavyweight boxing champion Anthony Joshua as brand ambassador amongst additional key product and brand development costs. The quantum of these costs are a long term investment which the board has approved to build Love Hemp into one of the UK's best known CBD and Wellness companies."

----------

Sabien Technology Group PLC - Watford-based boiler efficiency products - Pretax loss in six months to December 31 widens to GBP569,000 from GBP310,000 loss in same period a year prior. Revenue drops to GBP121,000 from GBP412,000. Administrative expenses rises to GBP639,000 from GBP522,000. Notes sales orders in first half falls to GBP278,000 from GBP362,000.

----------

Polarean Imaging PLC - North Carolina-based MRI equipment and medical-imaging technology company - Files resubmission of its new drug application with the US Food & Drug Administration for its investigational drug‑device combination product using hyperpolarised Xenon. "It is currently expected that the FDA review period will take six months. The company is making full use of this time with regards to commercialisation and launch preparation and will further update the market once material information is received," company adds.

----------

Feedback PLC - medical imaging software company - Says its cloud TB screening service is now live at the Evangelical Hospital Khariar in Odisha, India. "The pilot, run in partnership with Qure.ai and Amazon Web Services will now move into an evaluative stage where the system benefits will be measured as patients come through. In parallel the company will pursue a number of opportunities to commercialise the system, leveraging the evidence generated by the pilot," company adds.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - Signs clinical trial agreement with the Centre for Human Drug Research in the Netherlands for the completion of a bacterial lipopolysaccharide human challenge study of POLB 001, which is due to commence in June 2022. First results are expected before the end of 2022 at which point the company aims to "rapidly monetise" by partnering or out licensing the asset for further development.

----------

Pure Gold Mining Inc - Vancouver, Canada-based gold miner - Reports net loss in final three months of USD17.9 million, with net loss in 2021 of USD34.9 million. Revenue in final quarter of 2021 was USD15.9 million, with annual revenue at USD31.9 million. Gold produced and sold in final quarter 7,565 and 7,100 ounces, respectively. Annually, gold produced was 26,899 with gold sold at 25,238.

----------

Gem Diamonds Ltd - Lesotho and Botswana-focused diamond miner - Enters binding share sale agreement with Okwa Diamonds Ltd for the sale of 100% of the share capital of Gem Diamonds Botswana Proprietary Ltd, the owner of the Ghaghoo diamond mine in Botswana. Okwa Diamonds, an SPV company registered in Botswana, is owned by AIM-listed Vast Resources PLC. No financial details disclosed.

----------

Atalaya Mining PLC - mining company focused on Spain - Notes ICBC Standard Bank PLC plans to sell up to 30.7 million shares in company to institutional investors. The shares represent the entire holding of Yanggu Xiangguang Copper Co Ltd, which is held via its subsidiary, Hong Kong Xiangguang International Holdings Ltd, in company and is about 22.0% of its existing issued share capital. Says price of shares will be decided at the close of the bookbuild process. The placing is not being underwritten.

----------

Tectonic Gold PLC - Sydney-based mineral explorer in Australia and South Africa - Pretax loss in six months to December 31 widens to GBP198,977 from GBP60,084 in same period a year prior. Loss stems primarily from employee benefits and management fees rises sharply to GBP143,333 from GBP500. Corporate costs grows to GBP72,671 from GBP33,999. Does not generate revenue in either period. Company says: "During the half year to December 2021, the company ran a significant field campaign on the lead gold exploration project at Specimen Hill. Our partnership with London listed Kazera Global Investments PLC also delivered the further production of diamonds from the Alexkor site in South Africa."

----------

Anglo African Agriculture PLC - agriculture investment company - Attributable loss in year to October 31 narrows to GBP584,633 from a GBP1.0 million loss in the same period a year prior. Revenue from contracts slips to GBP1.4 million from GBP1.8 million. Chair Andrew Monk says period was "very disappointing". He adds: "AAA's primary operations and source of revenue remains Dynamic Intertrade, our Cape Town based spice blender and trader. The company's operations have been negatively affected by Covid-19 with sales in local currency falling 23.2% and 20.8% in reporting currency. This was primarily driven by the South African economy being impacted by Covid-19."

----------

Metal Tiger PLC - Winchester, England-based investment company focused on the natural resources sector - Pretax profit in 2021 rises to GBP4.2 million from GBP3.8 million in 2020. Investment income grows to GBP1.5 million from GBP648,000, while profit on investment disposals more than doubles to GBP2.0 million from GBP745,000. Chair Charles Hall says: "As the board looks to the future, there will be an increased focus on larger investments in advanced resource definition-development stage alongside the traditional high conviction earlier stage investments with a medium to long term investment timeframe and where we can obtain board representation. On the less active front the board has nearly exited all of its legacy positions and will be focusing on diversifying into shorter-medium term, lower risk, investment opportunities, to balance risk profiles against earlier stage investments."

----------

Technology Minerals PLC - London-based producer of battery metals from both mining and recycling of spent batteries - Delays publication of interim results. "This follows guidance from the Financial Conduct Authority on corporate reporting timetables in light of Covid-19 and will allow the company sufficient time to complete the process of preparing and reviewing the results," it explains. Says results will be issued no later than April 29.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.